Toenail infections might seem like minor inconveniences, but medical experts warn they can spiral into severe complications ...

Oric Pharmaceuticals (ORIC) announced data from a Phase 1b trial of enozertinib at the ESMO Asia Congress 2025. Data in previously treated NSCLC ...

Preliminary Activity Analysis In the 15 efficacy-evaluable patients in the 120 mg cohort, the majority of which received an effective dose of 80 mg QD, enozertinib demonstrated strong systemic and CNS ...

Hangnails are tiny, but the discomfort they cause can feel wildly disproportionate. One little snag near your nail bed and ...

SINGAPORE,First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients.

Initial data from a phase 2 (NCT05256290) clinical trial show that silevertinib yields robust antitumor activity and ...

Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended dose of 3 mg/m2 twice daily. Common adverse effects included weight gain, ...

HYRNUO is a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2). In vitro, HYRNUO inhibited the phosphorylation of HER2, downstream signaling in cancer cells with HER2 ...

Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development ...

Early Phase 1b data for enozertinib, presented at the ESMO Asia Congress 2025, show strong systemic and intracranial activity ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active ...